ResearcherAffiliated Hospital of Xuzhou Medical CollegeActive in the last 2 years

Wenxing Zhao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109267008. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

Deletion of ENO1 sensitizes pancreatic cancer cells to gemcitabine via MYC/RRM1-mediated glycolysis. Last author DOI 10.1038/s41598-025-94319-0 ↗
ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway. Last author DOI 10.1002/mc.23719 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hongqin Ma · 2 shared papers, 2024–2025 · strength 0.52
- Paper Deletion of ENO1 sensitizes pancreatic cancer cells to gemcitabine via MYC/RRM1-mediated glycolysis. DOI 10.1038/s41598-025-94319-0 ↗
- Paper ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway. DOI 10.1002/mc.23719 ↗
Li Liu · 2 shared papers, 2024–2025 · strength 0.52
- Paper Deletion of ENO1 sensitizes pancreatic cancer cells to gemcitabine via MYC/RRM1-mediated glycolysis. DOI 10.1038/s41598-025-94319-0 ↗
- Paper ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway. DOI 10.1002/mc.23719 ↗
Yingpeng Lu · 1 shared paper, 2025 · strength 0.28
- Paper Deletion of ENO1 sensitizes pancreatic cancer cells to gemcitabine via MYC/RRM1-mediated glycolysis. DOI 10.1038/s41598-025-94319-0 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.